Michael Gibney

1 week ago | pharmavoice.com | Michael Gibney

This audio is auto-generated. Please let us know if you have feedback. As the pharmaceutical industry wrestles with the prospect of U.S. tariffs and global retaliation that could cut into future profits, the changing dynamic has industry leaders considering capital allocation strategies that could shift priorities in a meaningful way.

2 weeks ago | pharmavoice.com | Michael Gibney

This audio is auto-generated. Please let us know if you have feedback. Following a week of President Donald Trump’s tariff tornado ripping through Wall Street, wiping out trillions in market value, the administration’s about-face on trade yesterday sent stocks soaring. Still, pharma companies that were spared from the taxes on imported goods have been spinning in the high winds.

2 weeks ago | pharmavoice.com | Michael Gibney

This audio is auto-generated. Please let us know if you have feedback. When Michelle Werner’s son Caffrey was diagnosed with Duchenne muscular dystrophy five years ago, she felt adrift. Lost in a fog. “We felt like we were marooned on an island in the middle of an ocean, completely alone and having to figure out how to fend for ourselves in a very foreign situation,” Werner said. A child’s rare disease diagnosis is devastating news.

3 weeks ago | pharmavoice.com | Michael Gibney

This audio is auto-generated. Please let us know if you have feedback. The fundamentals of leadership haven’t changed much in the more than three decades Dr. Mikael Dolsten has been a prominent figure in the pharma industry, most recently as chief scientific officer and president of R&D at Pfizer. But the world is changing rapidly, driven in part by technological advances like AI and the proliferation of data-driven approaches.

4 weeks ago | pharmavoice.com | Michael Gibney

This audio is auto-generated. Please let us know if you have feedback. What do you get when you combine the efforts of one of the world’s leading respiratory drugmakers with a global pioneer in biological medicines? You get a next-gen treatment like Tezspire, which according to pivotal results revealed this month, could become an important new therapy for an underserved respiratory condition.